A5018152581- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Blood disorders and treatments
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Hemoglobinopathies and Related Disorders
- Central Venous Catheters and Hemodialysis
- Innovations in Medical Education
- Gastrointestinal Tumor Research and Treatment
- Hematopoietic Stem Cell Transplantation
- Cardiac tumors and thrombi
- Mosquito-borne diseases and control
- Lung Cancer Treatments and Mutations
- Diagnosis and Treatment of Venous Diseases
- Healthcare professionals’ stress and burnout
- Vascular Tumors and Angiosarcomas
- Gastrointestinal disorders and treatments
- Kruppel-like factors research
- Empathy and Medical Education
- Lymphoma Diagnosis and Treatment
- Herpesvirus Infections and Treatments
- Venous Thromboembolism Diagnosis and Management
Mayo Clinic in Arizona
2021-2025
Mayo Clinic
2020-2024
St. Luke's Hospital
2023-2024
WinnMed
2023
Oregon Health & Science University
2020
Background: Medical student wellness, including physical health, emotional and levels of perceived stress, appears to decline during training, with students reporting high depression, anxiety, burnout as early the first year medical school. The impact curricular changes on health stress remains unclear, a modified curriculum that compresses training foundational sciences its effect wellness has not been studied. Oregon Health & Science University School Medicine recently instituted unique...
Abstract Venetoclax + hypomethylating agent (Ven‐HMA) is currently the standard frontline therapy for older/unfit patients with newly diagnosed acute myeloid leukemia (ND‐AML). Our objective in current retrospective study of 301 adult (median age 73 years; 62% de novo) ND‐AML was to identify molecular predictors treatment response Ven‐HMA and survival; European LeukemiaNet (ELN) genetic risk assignment favorable 15%, intermediate 16%, adverse 69%. Complete remission, (CR) or without (CRi),...
Not available.
Summary Among 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non‐ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four had more than one complication. Baseline characteristics included median age ± interquartile range; 73 years; 87% males; 96% cardiovascular risk factors; 90% preserved baseline ejection fraction. In multivariate analysis,...
Not available.
Patients with newly diagnosed acute myeloid leukemia (ND-AML) derive variable survival benefit from venetoclax + hypomethylating agent (Ven-HMA) therapy. The primary objective in the current study was to develop genetic risk models that are predictive of and applicable at time diagnosis after establishing treatment response. Among 400 ND-AML patients treated Ven-HMA Mayo Clinic, 247 (62%) achieved complete remission (CR) or without (CRi) count recovery. Multivariable analysis-derived hazard...
Venetoclax, a small-molecule inhibitor of B-cell lymphoma-2, in combination with the hypomethylating agents (HMA) azacitidine or decitabine, is FDA-approved for elderly/unfit patients acute myeloid leukemia (AML).It frequently used both upfront and relapsed/refractory setting based on superior efficacy improved survival regimen compared HMA alone.
Induction therapy for multiple myeloma with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (d) (VRd) was traditionally administered as given twice weekly on a 3 week cycle. A modified schedule of has been adopted over time to decrease treatment burden patients reduce treatment-emergent neuropathy. This study evaluates the response rates outcomes different schedules in VRd first-line newly diagnosed MM (NDMM). We retrospectively analyzed treated upfront from June 30th 2008...
Allogeneic stem cell transplantation (alloSCT) is the only known curative treatment for myelofibrosis (MF). Risk assessment remains important patient counseling and predicting survival outcomes relapse nonrelapse mortality (NRM). Outcome-prediction tools can guide decision-making. Their use in MF has relied on their extrapolation from other malignancies. The primary objective of this study was to assess performance Hematopoietic Transplantation Comorbidity Index (HCT-CI), augmented HCT-CI...
Adult intussusception is rare, highly associated with a malignant lead point, and often requires emergent surgical management. We report the case of 44-year-old male who presented generalized abdominal pain was found to have early ileocolic secondary large ileocecal mass. Biopsies mass an enlarged cardiophrenic lymph node, as well pleural fluid cytology were all consistent Burkitt lymphoma (BL). Curiously, patient’s exam reassuring, bowel obstruction resolved over 36 hours conservative...
Abstract Bony pain in patients with a history of myelofibrosis warrants further investigation. Although skeletal involvement is more commonly osteosclerosis or periostitis, it can also cause osteolytic lesions.